Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Expanded Access to RZ-001 in Combination with Valganciclovir in the Treatment of Subjects with Glioblastoma

NCT06676891 is registered in ClinicalTrials.gov with Rznomics, Inc. as lead sponsor.

NCT NCT06676891
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06676891 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Expanded Access to RZ-001 in Combination with Valganciclovir in the Treatment of Subjects with Glioblastoma
Lead sponsor
Rznomics, Inc.
Phase
Expanded access
Overall status
Available
Start date
Not reported
Completion date
Not reported
Enrollment
Not reported
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma